Short Term Effects of a Multimodal Intervention With RGM on Cognition in People With Parkinson's Disease.
NCT07863219
Summary
The goal of this clinical trial is to learn if the Ronnie Gardiner Method (RGM) works to improve cognitive functions in adults with Parkinson's disease (early to mid-stage). It will also learn about the secondary effects on speech, mobility, balance, and mood. The main questions it aims to answer are: * Does a 10-week RGM intervention improve cognitive aspects, speech (indirectly through improved breathing), mobility, and balance in participants with Parkinson's disease? * How do participants experience the intensity, difficulty, and emotional impact of the RGM sessions?
Eligibility
Inclusion Criteria: * diagnosis of idiopathic Parkinson's disease * safe, independent mobility and participation (Hoehn and Yahr stages 1-3) * a stable dopaminergic medication regimen for at least 4 weeks prior to study participation * willingness and ability to participate in a 10-week intervention program * willingness to participate in the study (signing of informed consent) Exclusion Criteria: * Presence of other neurological or severe psychiatric conditions that could interfere with participation or the interpretation of results (e.g., substance use disorder, severe depression, psychosis) * Severe visual or hearing impairments that limit the ability to follow group instructions as determined by a physician. * Physical limitations that inhibit safe participation in moderate-to-vigorous exercise or group rehabilitation.
Conditions5
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07863219